Prognostic factors and treatment effects for hepatocellular carcinoma in Child C cirrhosis

K. Nouso, Y. M. Ito, K. Kuwaki, Y. Kobayashi, S. Nakamura, Y. Ohashi, K. Yamamoto

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The aim of this study is to elucidate the prognostic factors and the treatment effect on survival in hepatocellular carcinoma (HCC) patients with Child C cirrhosis. Out of 3330 newly discovered HCC patients, 157 consecutive HCC individuals with Child C cirrhosis were enrolled. The prognostic factors were examined by Cox proportional hazards regression analysis and their survival was compared by propensity score-matched analysis. Multivariate analysis revealed that high serum bilirubin (>3 mg dl-1), the presence of uncontrollable ascites, and a high platelet count (>8 × 104 mm-3), so-called background liver factors, as well as multiple tumours, large tumours (>3 cm), high alpha-fetoprotein (>400 ng ml -1), and the presence of portal vein thrombus, so-called tumour factors, were factors of poor prognosis. While transcatheter arterial chemoembolisation (TACE) was a factor of good prognosis (relative risk=0.50, 95%CI=0.27-0.89, P=0.019), local ablation therapy and transcatheter arterial chemoinfusion (TAI) were not significant prognostic factors. The survival of patients who received TACE was superior to matched patients without active treatment (P=0.009); however, we did not observe survival benefit after local ablation therapy or TAI. These results suggested that tumour factors as well as background liver factors are prognostic factors of HCC even in patients with Child C cirrhosis, and selective use of TACE in these patients provides survival benefit.

Original languageEnglish
Pages (from-to)1161-1165
Number of pages5
JournalBritish Journal of Cancer
Volume98
Issue number7
DOIs
Publication statusPublished - Apr 8 2008

Fingerprint

Hepatocellular Carcinoma
Fibrosis
Survival
Neoplasms
Therapeutics
Propensity Score
Liver
alpha-Fetoproteins
Portal Vein
Platelet Count
Bilirubin
Ascites
Thrombosis
Multivariate Analysis
Regression Analysis
Serum

Keywords

  • Decompensated cirrhosis
  • Hepatocellular carcinoma
  • Prognostic factors
  • Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nouso, K., Ito, Y. M., Kuwaki, K., Kobayashi, Y., Nakamura, S., Ohashi, Y., & Yamamoto, K. (2008). Prognostic factors and treatment effects for hepatocellular carcinoma in Child C cirrhosis. British Journal of Cancer, 98(7), 1161-1165. https://doi.org/10.1038/sj.bjc.6604282

Prognostic factors and treatment effects for hepatocellular carcinoma in Child C cirrhosis. / Nouso, K.; Ito, Y. M.; Kuwaki, K.; Kobayashi, Y.; Nakamura, S.; Ohashi, Y.; Yamamoto, K.

In: British Journal of Cancer, Vol. 98, No. 7, 08.04.2008, p. 1161-1165.

Research output: Contribution to journalArticle

Nouso, K, Ito, YM, Kuwaki, K, Kobayashi, Y, Nakamura, S, Ohashi, Y & Yamamoto, K 2008, 'Prognostic factors and treatment effects for hepatocellular carcinoma in Child C cirrhosis', British Journal of Cancer, vol. 98, no. 7, pp. 1161-1165. https://doi.org/10.1038/sj.bjc.6604282
Nouso, K. ; Ito, Y. M. ; Kuwaki, K. ; Kobayashi, Y. ; Nakamura, S. ; Ohashi, Y. ; Yamamoto, K. / Prognostic factors and treatment effects for hepatocellular carcinoma in Child C cirrhosis. In: British Journal of Cancer. 2008 ; Vol. 98, No. 7. pp. 1161-1165.
@article{e3c1bc849f6e43b9b313b9a2635577d0,
title = "Prognostic factors and treatment effects for hepatocellular carcinoma in Child C cirrhosis",
abstract = "The aim of this study is to elucidate the prognostic factors and the treatment effect on survival in hepatocellular carcinoma (HCC) patients with Child C cirrhosis. Out of 3330 newly discovered HCC patients, 157 consecutive HCC individuals with Child C cirrhosis were enrolled. The prognostic factors were examined by Cox proportional hazards regression analysis and their survival was compared by propensity score-matched analysis. Multivariate analysis revealed that high serum bilirubin (>3 mg dl-1), the presence of uncontrollable ascites, and a high platelet count (>8 × 104 mm-3), so-called background liver factors, as well as multiple tumours, large tumours (>3 cm), high alpha-fetoprotein (>400 ng ml -1), and the presence of portal vein thrombus, so-called tumour factors, were factors of poor prognosis. While transcatheter arterial chemoembolisation (TACE) was a factor of good prognosis (relative risk=0.50, 95{\%}CI=0.27-0.89, P=0.019), local ablation therapy and transcatheter arterial chemoinfusion (TAI) were not significant prognostic factors. The survival of patients who received TACE was superior to matched patients without active treatment (P=0.009); however, we did not observe survival benefit after local ablation therapy or TAI. These results suggested that tumour factors as well as background liver factors are prognostic factors of HCC even in patients with Child C cirrhosis, and selective use of TACE in these patients provides survival benefit.",
keywords = "Decompensated cirrhosis, Hepatocellular carcinoma, Prognostic factors, Therapy",
author = "K. Nouso and Ito, {Y. M.} and K. Kuwaki and Y. Kobayashi and S. Nakamura and Y. Ohashi and K. Yamamoto",
year = "2008",
month = "4",
day = "8",
doi = "10.1038/sj.bjc.6604282",
language = "English",
volume = "98",
pages = "1161--1165",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Prognostic factors and treatment effects for hepatocellular carcinoma in Child C cirrhosis

AU - Nouso, K.

AU - Ito, Y. M.

AU - Kuwaki, K.

AU - Kobayashi, Y.

AU - Nakamura, S.

AU - Ohashi, Y.

AU - Yamamoto, K.

PY - 2008/4/8

Y1 - 2008/4/8

N2 - The aim of this study is to elucidate the prognostic factors and the treatment effect on survival in hepatocellular carcinoma (HCC) patients with Child C cirrhosis. Out of 3330 newly discovered HCC patients, 157 consecutive HCC individuals with Child C cirrhosis were enrolled. The prognostic factors were examined by Cox proportional hazards regression analysis and their survival was compared by propensity score-matched analysis. Multivariate analysis revealed that high serum bilirubin (>3 mg dl-1), the presence of uncontrollable ascites, and a high platelet count (>8 × 104 mm-3), so-called background liver factors, as well as multiple tumours, large tumours (>3 cm), high alpha-fetoprotein (>400 ng ml -1), and the presence of portal vein thrombus, so-called tumour factors, were factors of poor prognosis. While transcatheter arterial chemoembolisation (TACE) was a factor of good prognosis (relative risk=0.50, 95%CI=0.27-0.89, P=0.019), local ablation therapy and transcatheter arterial chemoinfusion (TAI) were not significant prognostic factors. The survival of patients who received TACE was superior to matched patients without active treatment (P=0.009); however, we did not observe survival benefit after local ablation therapy or TAI. These results suggested that tumour factors as well as background liver factors are prognostic factors of HCC even in patients with Child C cirrhosis, and selective use of TACE in these patients provides survival benefit.

AB - The aim of this study is to elucidate the prognostic factors and the treatment effect on survival in hepatocellular carcinoma (HCC) patients with Child C cirrhosis. Out of 3330 newly discovered HCC patients, 157 consecutive HCC individuals with Child C cirrhosis were enrolled. The prognostic factors were examined by Cox proportional hazards regression analysis and their survival was compared by propensity score-matched analysis. Multivariate analysis revealed that high serum bilirubin (>3 mg dl-1), the presence of uncontrollable ascites, and a high platelet count (>8 × 104 mm-3), so-called background liver factors, as well as multiple tumours, large tumours (>3 cm), high alpha-fetoprotein (>400 ng ml -1), and the presence of portal vein thrombus, so-called tumour factors, were factors of poor prognosis. While transcatheter arterial chemoembolisation (TACE) was a factor of good prognosis (relative risk=0.50, 95%CI=0.27-0.89, P=0.019), local ablation therapy and transcatheter arterial chemoinfusion (TAI) were not significant prognostic factors. The survival of patients who received TACE was superior to matched patients without active treatment (P=0.009); however, we did not observe survival benefit after local ablation therapy or TAI. These results suggested that tumour factors as well as background liver factors are prognostic factors of HCC even in patients with Child C cirrhosis, and selective use of TACE in these patients provides survival benefit.

KW - Decompensated cirrhosis

KW - Hepatocellular carcinoma

KW - Prognostic factors

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=41649108003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41649108003&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6604282

DO - 10.1038/sj.bjc.6604282

M3 - Article

C2 - 18349849

AN - SCOPUS:41649108003

VL - 98

SP - 1161

EP - 1165

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 7

ER -